CYP19A1 and breast carcinoma: Several large‐scale long‐term follow‐up studies, including ABCSG XII, ASTRRA, TEXT, SOFT, and ZIPP underscore the benefits of ovarian function suppression (OFS) when combined with an aromatase inhibitor (AI) or tamoxifen for premenopausal HR‐positive breast cancer patients.10, 11, 12, 13